CN111135280A - A pharmaceutical composition, ointment and plaster for treating arthritis - Google Patents

A pharmaceutical composition, ointment and plaster for treating arthritis Download PDF

Info

Publication number
CN111135280A
CN111135280A CN202010041930.7A CN202010041930A CN111135280A CN 111135280 A CN111135280 A CN 111135280A CN 202010041930 A CN202010041930 A CN 202010041930A CN 111135280 A CN111135280 A CN 111135280A
Authority
CN
China
Prior art keywords
parts
stearate
glycerol
extract
ointment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010041930.7A
Other languages
Chinese (zh)
Inventor
王荣成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weihai Shenglang Biotechnology Co ltd
Original Assignee
Weihai Shenglang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weihai Shenglang Biotechnology Co ltd filed Critical Weihai Shenglang Biotechnology Co ltd
Priority to CN202010041930.7A priority Critical patent/CN111135280A/en
Publication of CN111135280A publication Critical patent/CN111135280A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a pharmaceutical composition, an ointment and a plaster for treating arthritis, which solve the technical problem of poor effect of the existing medicines for treating arthritis and comprise the following components in parts by weight: 5-8 parts of liquid paraffin; 5-7 parts of isopropyl palmitate; 4-7 parts of cetearyl alcohol; 4-7 parts of glycerol; 4-7 parts of menthol; 4-7 parts of chitosamine HCL; 4-6 parts of dimethyl sulfone; 3.5-5 parts of emu oil; 3.5-5 parts of squalane; polysorbate-603-5 parts; 2.5-4 parts of beeswax; 2.5-4 parts of camphor; 2.5-4 parts of chondroitin sodium sulfate; 1.5-3 parts of eucalyptol; 1.5-3 parts of mussel extract; 1.5-3 parts of borneol; 1.5-3 parts of tocopherol acetate; 1-2.5 parts of an extract of amur cork tree bark; 1-2.5 parts of polydimethylsiloxane; 0.5-2 parts of sorbitan stearate; 0.5-2 parts of glycerol stearate; 0.5-2 parts of PEG-100 stearate and the like; also provides an ointment and a plaster prepared from the raw materials, and can be widely applied to the field of medicines.

Description

A pharmaceutical composition, ointment and plaster for treating arthritis
Technical Field
The invention relates to the field of medicaments, in particular to a medicinal component, an ointment and a plaster for treating arthritis.
Background
Arthritis generally refers to inflammatory diseases occurring in human joints and surrounding tissues, is mainly clinically manifested by symptoms of joint pain, joint swelling, joint dysfunction and the like, has the characteristics of high morbidity and high disability rate, and is particularly harmful to middle-aged and elderly people.
In the prior art, arthritis is mainly treated by physical therapy, drug therapy and operative therapy according to the degree of severity.
The mild arthritis mostly adopts conservative physical therapy, including physical therapy such as light, electricity, heat, magnetism and the like and exercise, and mainly has the effects of diminishing inflammation, relieving pain, increasing or keeping the range of motion of each joint, satisfying functional activities and preventing deformity. The long-term adherence and the attention to the daily conditioning and protection can achieve the effect of maintaining the current situation and avoid further deterioration.
Mild to moderate arthritis can be controlled by taking medication. The drug therapy can be divided into oral administration and external application. The traditional therapeutic drugs for arthritis mainly comprise non-steroidal anti-inflammatory drugs such as acetaminophen, diclofenac and the like, and are mainly taken orally. The non-steroidal anti-inflammatory drugs taken orally have obvious side effects on gastrointestinal tracts, kidneys and livers, and the drugs can cause discomfort of digestive tracts, such as nausea and vomiting and increase the risk of digestive tract bleeding. The importance of basic drug combination therapy is highlighted by the fact that arthritis can only be treated with temporary relief at the expense of organ damage.
The topical medicine includes topical medicine such as plaster; applying externally, or applying externally, such as medicinal oil, medicated wine extract, etc. Topical application of ointment or patch, similar to analgesic drugs, is also a symptomatic relief and does not delay the progression of arthritis. But due to topical application, have fewer side effects than analgesic drugs, but are less effective.
Surgical therapy is a common treatment for patients with severe arthritis. The surgical treatment mainly comprises joint cavity puncture, synovium resection, joint replacement, joint orthopaedics, joint fusion and the like. However, the problem of high risk, difficult postoperative recovery and high operation cost in the operation of arthritis treatment, especially the problems of long-term effect after operation, infection complications and the like, can aggravate the pain of patients.
Therefore, the prior art lacks a medicament for treating arthritis, which is safe to use, has no side effect and has good treatment effect.
Disclosure of Invention
The invention aims to solve the technical defects, and provides a medicinal component, an ointment and a plaster for treating arthritis, which are safe to use, have no side effect and have good treatment effect.
Therefore, the invention provides a medicine component for treating arthritis, which comprises the following components in parts by weight: 5-8 parts of liquid paraffin; 5-7 parts of isopropyl palmitate; 4-7 parts of cetearyl alcohol; 4-7 parts of glycerol; 4-7 parts of menthol; 4-7 parts of chitosamine HCL; 4-6 parts of dimethyl sulfone; 3.5-5 parts of emu oil; 3.5-5 parts of squalane; 3-5 parts of polysorbate-60; 2.5-4 parts of beeswax; 2.5-4 parts of camphor; 2.5-4 parts of chondroitin sodium sulfate; 1.5-3 parts of eucalyptol; 1.5-3 parts of mussel extract; 1.5-3 parts of borneol; 1.5-3 parts of tocopherol acetate; 1-2.5 parts of an extract of the amur cork tree bark; 1-2.5 parts of polydimethylsiloxane; 0.5-2 parts of sorbitan stearate; 0.5-2 parts of glycerol stearate; 0.5-2 parts of PEG-100 stearate; 0.5-2 parts of stearic acid; ginger root oil 0.5-2 parts; 0.15-0.3 part of xanthan gum; 0.1-0.25 parts of methyl hydroxybenzoate; 0.08-0.2 part of hydroxy phenylpropyl ester; 0.1-0.2 parts of imidazolidinyl urea; 0.05-0.15 part of EDTA disodium; and a proper amount of water.
In the above technical solution, further, the composition comprises, by weight: 5-7 parts of liquid paraffin; 5-6 parts of isopropyl palmitate; 4-6 parts of cetearyl alcohol; 4-6 parts of glycerol; 4-6 parts of menthol; 4-6 parts of chitosamine HCL; 4-5 parts of dimethyl sulfone; 3.5-4.5 parts of emu oil; 3.5-4.5 parts of squalane; 3-4 parts of polysorbate-60; 2.5-3.5 parts of beeswax; 2.5-3.5 parts of camphor; 2.5-3.5 parts of chondroitin sodium sulfate; 1.5-2.5 parts of eucalyptol; 1.5-2.5 parts of mussel extract; 1.5-2.5 parts of borneol; 1.5-2.5 parts of tocopherol acetate; 1-2 parts of an extract of the amur cork tree bark; 1-2 parts of polydimethylsiloxane; 0.5-1.5 parts of sorbitan stearate; 0.5-1.5 parts of glycerol stearate; 0.5-1.5 parts of PEG-100 stearate; 0.5-1.5 parts of stearic acid; ginger root oil 0.5-1.5 weight portions; 0.15-0.25 parts of xanthan gum; 0.1-0.2 parts of methyl hydroxybenzoate; 0.08-0.15 part of hydroxy phenylpropyl ester; 0.1-0.15 parts of imidazolidinyl urea; 0.05-0.1 part of EDTA disodium; and a proper amount of water.
In the above technical solution, further, the composition comprises, by weight: 26.87 parts of water; 6 parts of liquid paraffin; 5.5 parts of isopropyl palmitate; 5 parts of cetearyl alcohol; 5 parts of glycerol; 5 parts of menthol; 5 parts of chitosamine HCL; 4.5 parts of dimethyl sulfone; 4 portions of emu oil; 4 parts of squalane; 3.5 parts of polysorbate-60; 3 parts of beeswax; 3 parts of camphor; 3 parts of chondroitin sodium sulfate; 2 parts of eucalyptol; mussel extract 2 parts; 2 parts of borneol; 2 parts of tocopherol acetate; 1.5 parts of an extract of the amur cork tree bark; 1.5 parts of polydimethylsiloxane; 1 part of sorbitan stearate; 1 part of glycerol stearate; 1 part of PEG-100 stearate; 1 part of stearic acid; 1 part of ginger root oil; 0.2 part of xanthan gum; 0.15 part of methylparaben; 0.1 part of hydroxy phenylpropyl ester; 0.13 part of imidazolidinyl urea; 0.05 part of disodium EDTA.
In addition, the invention also provides an ointment for treating arthritis, which comprises the following components in parts by weight: 5-8 parts of liquid paraffin; 5-7 parts of isopropyl palmitate; 4-7 parts of cetearyl alcohol; 4-7 parts of glycerol; 4-7 parts of menthol; 4-7 parts of chitosamine HCL; 4-6 parts of dimethyl sulfone; 3.5-5 parts of emu oil; 3.5-5 parts of squalane; 3-5 parts of polysorbate-60; 2.5-4 parts of beeswax; 2.5-4 parts of camphor; 2.5-4 parts of chondroitin sodium sulfate; 1.5-3 parts of eucalyptol; 1.5-3 parts of mussel extract; 1.5-3 parts of borneol; 1.5-3 parts of tocopherol acetate; 1-2.5 parts of an extract of the amur cork tree bark; 1-2.5 parts of polydimethylsiloxane; 0.5-2 parts of sorbitan stearate; 0.5-2 parts of glycerol stearate; 0.5-2 parts of PEG-100 stearate; 0.5-2 parts of stearic acid; ginger root oil 0.5-2 parts; 0.15-0.3 part of xanthan gum; 0.1-0.25 parts of methyl hydroxybenzoate; 0.08-0.2 part of hydroxy phenylpropyl ester; 0.1-0.2 parts of imidazolidinyl urea; 0.05-0.15 part of EDTA disodium; and a proper amount of water.
In the above technical solution, further, the composition comprises, by weight: 5-7 parts of liquid paraffin; 5-6 parts of isopropyl palmitate; 4-6 parts of cetearyl alcohol; 4-6 parts of glycerol; 4-6 parts of menthol; 4-6 parts of chitosamine HCL; 4-5 parts of dimethyl sulfone; 3.5-4.5 parts of emu oil; 3.5-4.5 parts of squalane; 3-4 parts of polysorbate-60; 2.5-3.5 parts of beeswax; 2.5-3.5 parts of camphor; 2.5-3.5 parts of chondroitin sodium sulfate; 1.5-2.5 parts of eucalyptol; 1.5-2.5 parts of mussel extract; 1.5-2.5 parts of borneol; 1.5-2.5 parts of tocopherol acetate; 1-2 parts of an extract of the amur cork tree bark; 1-2 parts of polydimethylsiloxane; 0.5-1.5 parts of sorbitan stearate; 0.5-1.5 parts of glycerol stearate; 0.5-1.5 parts of PEG-100 stearate; 0.5-1.5 parts of stearic acid; ginger root oil 0.5-1.5 weight portions; 0.15-0.25 parts of xanthan gum; 0.1-0.2 parts of methyl hydroxybenzoate; 0.08-0.15 part of hydroxy phenylpropyl ester; 0.1-0.15 parts of imidazolidinyl urea; 0.05-0.1 part of EDTA disodium; and a proper amount of water.
In the above technical solution, further, the composition comprises, by weight: 26.87 parts of water; 6 parts of liquid paraffin; 5.5 parts of isopropyl palmitate; 5 parts of cetearyl alcohol; 5 parts of glycerol; 5 parts of menthol; 5 parts of chitosamine HCL; 4.5 parts of dimethyl sulfone; 4 portions of emu oil; 4 parts of squalane; 3.5 parts of polysorbate-60; 3 parts of beeswax; 3 parts of camphor; 3 parts of chondroitin sodium sulfate; 2 parts of eucalyptol; mussel extract 2 parts; 2 parts of borneol; 2 parts of tocopherol acetate; 1.5 parts of an extract of the amur cork tree bark; 1.5 parts of polydimethylsiloxane; 1 part of sorbitan stearate; 1 part of glycerol stearate; 1 part of PEG-100 stearate; 1 part of stearic acid; 1 part of ginger root oil; 0.2 part of xanthan gum; 0.15 part of methylparaben; 0.1 part of hydroxy phenylpropyl ester; 0.13 part of imidazolidinyl urea; 0.05 part of disodium EDTA.
In addition, the invention also provides a plaster for treating arthritis, which comprises a sheet-shaped substrate, wherein the sheet-shaped substrate is provided with an adhesive part and a medicine placing part, and the medicine placing part is provided with a medicine component for treating arthritis according to any one of claims 1 to 3.
The raw materials of the invention have the following functions:
water: a solvent; deionized water is typically used.
Liquid paraffin: as a smooth humectant, excipient and penetration enhancer.
Isopropyl palmitate: as a decomposition suspending agent, the emulsion is beneficial to uniform smearing, makes the skin soft and increases the scrub resistance; can be used as emollient, oleaginous carrier, and solvent.
Cetyl stearyl alcohol: the product can be used as emollient, emulsifier and thickener to help the product easily penetrate into the skin and enter the joint, and can also be used as emulsifier to make the product more easily smeared.
Glycerol: can be used as plasticizer, penetration enhancer and humectant.
Menthol: as a penetration enhancer; has refreshing and analgesic effects; has certain bacteriostasis capacity.
Chitosamine HCL: strengthening immunity, and regulating nervous system and endocrine system of plant; has promoting effect on the treatment of arthritis.
Dimethyl sulfone: the joint cartilage repairing liquid has the advantages of nourishing essence, promoting cartilage regeneration, promoting joint synovial fluid generation, repairing damaged joint cartilage, lubricating the surface of the joint cartilage, reducing friction and vibration between bone joints, enabling the cartilage to become smoother, thicker and elastic, recovering normal motion function of joints, and maintaining the joint cartilage for a long time.
Emu oil: has deep penetration ability, and can be used for relieving muscle pain and arthritis.
Squalane: has good antioxidant effect and immunity stimulating effect, good stability, no oxidation with air and ultraviolet rays, good permeability, high oxygen carrying capacity, and can regulate water and oil balance of skin.
Polysorbate-60: as an emulsifier, the emulsion can prevent the small droplets of the dispersed phase from coagulating and the formed emulsion is relatively stable.
Beeswax: as a stabilizer, the material has the characteristics of good plasticity, oxidation and deterioration resistance and the like; has antibacterial, antiinflammatory, toxic substance removing, and analgesic effects, and is prepared from Cera flava rich in antibacterial components for inhibiting and killing pathogenic bacteria, and Cera flava also has effects in removing necrotic tissue and promoting granulation.
Camphor: has the local effect on joint parts, and has mild stimulation and antiseptic effect when being applied to skin; it can be applied forcefully to treat reddening hair; when lightly applied, the product is similar to mint and has cool feeling; also mild local anesthetic effect.
Sodium chondroitin sulfate: can stimulate secretion of joint body fluid and lubricating fluid between joints, is helpful for cartilage to absorb nutrition, has high elasticity, simultaneously reduces the activity of cartilage decomposition enzyme, prevents cartilage from degrading in advance, promotes bone healing, and can be used for treating arthritis.
Eucalyptol: as an additive; has strong antibacterial and disinfectant effects.
Mussel extract: is extracted from meat of marine animals belonging to Mytilus, mainly from meat of Mytilus edulis, perna viridis, Mytilus glaucoides and Mytilus coruscus, has arthritis preventing and treating activity, and can be used alone or together with other medicines as active ingredients to prepare health food or medicine for preventing and treating arthritis.
Borneol: has antibacterial and antiinflammatory effects, has slight irritation to sensory nerve, has analgesic and mild antiseptic effects, and can be used for treating neuralgia.
Tocopherol acetate: belongs to vitamin E derivatives, has strong reducibility, and can be used as antioxidant for eliminating free radicals in vivo and preventing aging.
Extract of bark of amur cork tree (phellodentron AMURENSE): as antioxidants, skin conditioners, antimicrobials; can promote the generation of collagen, and has the function of anti-aging by combining the oxidation resistance; has anti-inflammatory and odor inhibiting effects.
Polydimethylsiloxane: as an emollient, it has a lubricating effect.
Sorbitan stearate: as a nonionic surfactant and an emulsifier, the water-soluble antibacterial moisturizing emulsion has the functions of emulsifying water and an oily solvent to accelerate permeation and slightly resisting bacteria and moisturizing.
Glycerol stearate: has good hydrolysis resistance, strong emulsifying property, excellent functions of emulsification, dispersion, solubilization, wetting, diffusion, antioxidation, sterilization, aging prevention and the like, and good compatibility with skin.
PEG-100 stearate: as an emulsifier, it is possible to improve the surface tension between the various constituent phases in the emulsion and to form a uniform and stable dispersion or emulsion.
Stearic acid: as a stabilizer, the suspending agent helps emulsification and has the effect of suspension stabilization.
Ginger (ZINGIBER OFFICINALE) root oil: can remove moisture in vivo, and promote blood circulation for removing blood stasis; has certain inhibiting effect on dermatophytes, streptomyces albus and oral pathogens; can enhance skin activity, activate skin, and has antioxidant and antiaging effects; it also has moisture keeping and odor inhibiting effects.
Xanthan gum: is biological glue integrating thickening, suspending, emulsifying and stabilizing; the suspension has good suspension effect on insoluble solids and oil drops; can be quickly dissolved in water and has good water solubility; has the characteristics of low concentration and high viscosity, and is a high-efficiency thickening agent; the pseudoplasticity is very outstanding, and the method is extremely effective for stabilizing suspension and emulsion; the viscosity of the xanthan gum solution has good stability to heat, acid, alkali, salt and enzymolysis.
Methyl hydroxybenzoate: has broad-spectrum antibacterial activity, can inhibit gram-negative and gram-positive bacteria, has stronger inhibition effect on saccharomycetes and mould, and has the advantages of low use concentration, broad spectrum, high efficiency, safety, economy and long service life compared with the traditional antiseptic product.
Propyl hydroxybenzoate: as an antibacterial preservative, the bactericidal composition has extremely strong bactericidal property.
Imidazolidinyl urea: as a preservative, it is mainly used for inhibiting the proliferation of microorganisms.
Disodium EDTA: the metal ion chelating agent is used as a chelating agent, a preservative, an antioxidant synergist and a processing aid, has an antioxidant effect, and has a strong chelating effect on metal ions to be used as a stabilizer.
The invention has the beneficial effects that: the invention provides a pharmaceutical composition, an ointment and a plaster for treating arthritis, which adopt raw materials of preparation grade or pharmaceutical grade, are safe to use and have no side effect; after the composition is prepared from multiple raw materials with the performances of oxidation resistance, antibiosis, inflammation diminishing, penetration promotion and the like, the anti-inflammatory effect is more comprehensive, the synergistic effect is achieved through combination, the effective absorption rate of an arthritis affected part is greatly improved, the composition is smeared on the joint with arthritis on the premise that the body inhibition is generated without increasing the burden on the arthritis affected part, the arthralgia is relieved, and the arthritis treatment effect is remarkable.
Detailed Description
The present invention will be further described with reference to specific examples to assist understanding of the invention. The method used in the invention is a conventional method if no special provisions are made; the raw materials and the apparatus used are, unless otherwise specified, conventional commercially available products.
Example 1:
the ointment for treating arthritis provided by the embodiment comprises the following components in parts by weight: 5 parts of liquid paraffin; 5 parts of isopropyl palmitate; 4 parts of cetearyl alcohol; 4 parts of glycerol; 4 parts of menthol; 4 parts of chitosamine HCL; 4 parts of dimethyl sulfone; emu oil 3.5 parts; 3.5 parts of squalane; the polysorbate-60 accounts for 3 parts; 2.5 parts of beeswax; 2.5 parts of camphor; 2.5 parts of chondroitin sodium sulfate; 1.5 parts of eucalyptol; mussel extract 1.5 parts; 1.5 parts of borneol; 1.5 parts of tocopherol acetate; 1 part of amur cork tree bark extract; 1 part of polydimethylsiloxane; sorbitan stearate 0.5 parts; 0.5 part of glycerol stearate; 0.5 part of PEG-100 stearate; 0.5 part of stearic acid; ginger root oil 0.5 weight portions; 0.15 part of xanthan gum; 0.1 part of methyl hydroxybenzoate; 0.08 portion of propyl hydroxybenzoate; 0.1 part of imidazolidinyl urea; 0.05 part of EDTA disodium; proper amount of water is added until the final product is in an ointment shape. The above raw materials are mixed and stirred by conventional method to obtain ointment for treating arthritis.
Example 2:
the ointment for treating arthritis provided by the embodiment comprises the following components in parts by weight: 26.87 parts of water; 6 parts of liquid paraffin; 5.5 parts of isopropyl palmitate; 5 parts of cetearyl alcohol; 5 parts of glycerol; 5 parts of menthol; 5 parts of chitosamine HCL; 4.5 parts of dimethyl sulfone; 4 portions of emu oil; 4 parts of squalane; 3.5 parts of polysorbate-60; 3 parts of beeswax; 3 parts of camphor; 3 parts of chondroitin sodium sulfate; 2 parts of eucalyptol; mussel extract 2 parts; 2 parts of borneol; 2 parts of tocopherol acetate; 1.5 parts of an extract of the amur cork tree bark; 1.5 parts of polydimethylsiloxane; 1 part of sorbitan stearate; 1 part of glycerol stearate; 1 part of PEG-100 stearate; 1 part of stearic acid; 1 part of ginger root oil; 0.2 part of xanthan gum; 0.15 part of methylparaben; 0.1 part of hydroxy phenylpropyl ester; 0.13 part of imidazolidinyl urea; 0.05 part of disodium EDTA. The above raw materials are mixed and stirred by conventional method to obtain ointment for treating arthritis.
Example 3:
the ointment for treating arthritis provided by the embodiment comprises the following components in parts by weight: 7 parts of liquid paraffin; 6 parts of isopropyl palmitate; the cetearyl alcohol accounts for 6 parts; 6 parts of glycerol; 6 parts of menthol; 6 parts of chitosamine HCL; 5 parts of dimethyl sulfone; 4.5 parts of emu oil; 4.5 parts of squalane; 4 parts of polysorbate-60; 3.5 parts of beeswax; 3.5 parts of camphor; 3.5 parts of chondroitin sodium sulfate; 2.5 parts of eucalyptol; mussel extract 2.5 parts; 2.5 parts of borneol; 2.5 parts of tocopherol acetate; 2 parts of an extract of the amur cork tree bark; 2 parts of polydimethylsiloxane; 1.5 parts of sorbitan stearate; 1.5 parts of glycerol stearate; 1.5 parts of PEG-100 stearate; 1.5 parts of stearic acid; 1.5 parts of ginger root oil; 0.25 part of xanthan gum; 0.2 part of methyl hydroxybenzoate; 0.15 part of propyl hydroxybenzoate; 0.15 part of imidazolidinyl urea; 0.1 part of EDTA disodium; proper amount of water is added until the final product is in an ointment shape. The above raw materials are mixed and stirred by conventional method to obtain ointment for treating arthritis.
Example 4:
the ointment for treating arthritis provided by the embodiment comprises the following components in parts by weight: 8 parts of liquid paraffin; 7 parts of isopropyl palmitate; 7 parts of cetearyl alcohol; 7 parts of glycerol; 7 parts of menthol; chitosamine HCL 7 parts; 6 parts of dimethyl sulfone; 5 parts of emu oil; 5 parts of squalane; 5 parts of polysorbate-60; 4 parts of beeswax; 4 parts of camphor; 4 parts of chondroitin sodium sulfate; 3 parts of eucalyptol; mussel extract 3 parts; 3 parts of borneol; 3 parts of tocopherol acetate; 2.5 parts of an extract of the amur cork tree bark; 2.5 parts of polydimethylsiloxane; 2 parts of sorbitan stearate; 2 parts of glycerol stearate; 2 parts of PEG-100 stearate; 2 parts of stearic acid; 2 parts of ginger root oil; 0.3 part of xanthan gum; 0.25 part of methylparaben; 0.2 part of hydroxy phenylpropyl ester; 0.2 part of imidazolidinyl urea; 0.15 part of EDTA disodium; proper amount of water is added until the final product is in an ointment shape. The above raw materials are mixed and stirred by conventional method to obtain ointment for treating arthritis.
Examples 1-4, together with a control group, were subjected to clinical trials.
First, 100 patients with different degrees of disease were selected.
Wherein the different degrees of disorders are classified as follows:
pain or discomfort during night bed rest (0 is absent, 4 is extreme pain);
pain or discomfort when walking on level ground (0 is absent, 4 is extreme pain);
pain or discomfort while walking up and down stairs (0 is absent, 4 is extremely painful);
severity of joint stiffness at first activity after morning waking (0 is none, 4 is extreme pain or discomfort);
severity of stiffness at later sitting, lying and rest (0 is none, 4 is extreme pain or discomfort);
the degree of difficulty that occurs going downstairs (0 is none, 4 is extreme pain or discomfort);
the degree of difficulty that occurs upstairs (0 is nothing, 4 is extreme pain or discomfort);
difficulty level of walking on uneven ground (0 is none, 4 is extreme pain or discomfort);
difficulty of squatting or bending the knee (0 is none, 4 is extreme pain or discomfort).
Note: all of the above are recorded in the past 48 h; the remaining 9 questions, except item 1, were scored on a 100mm scale for 36 points, and the degree of weight of knee OA was evaluated according to the following criteria for the total points: the mild degree is less than 10 points; medium 10-18 points; severe > 18 points.
Namely 100 patients with mild arthritis, 100 patients with moderate arthritis and 100 patients with severe arthritis are selected.
The first clinical test is as follows:
the patients with mild arthritis are averagely divided into 5 groups, each group comprises 20 patients, the medicine coating amount of each patient is the same, and the medicine amount influence factors are eliminated.
The ointment provided in example 1 was used by the first group of patients for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The second group of patients used the ointment provided in example 2 for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The third group of patients used the ointment for treating arthritis provided in example 3, using the method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The ointment for treating arthritis provided in example 4 was applied to a fourth group of patients by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The fifth group of patients served as a control group and used commercially available ibuprofen gel ointment for treating arthritis by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
After one treatment course, the treatment effect of each group of patients is counted, and the treatment effect is divided into clinical recovery, significant effect, effective effect and ineffective effect; the classification criteria are as follows:
the clinical cure is as follows: the pain and swelling of the knee joint disappear, the activity function returns to normal, the tenderness or patella test is negative, the laboratory test is normal, and the integral value is zero;
the effect is shown: knee joint pain and swelling disappear or are obviously relieved, the activity is obviously improved, the tenderness or floating body test is negative, and the integral value is reduced to be more than 2/3;
the method has the following advantages: the pain and swelling of the knee joint are reduced, the activity is improved, the tenderness or the floating skeleton test is weak and positive, and the integral value is reduced to be more than 1/3;
and (4) invalidation: those with symptoms and signs not improved by the above criteria and with an integral value decreased by < 1/3.
The test results are shown in table 1:
TABLE 1 results of clinical trial 1
Figure BDA0002368059490000111
As shown in table 1, the clinical cure rates of the four groups of ointments for treating arthritis provided by the application are 80%, 75% and 70% for patients with mild arthritis; the significant efficiency is respectively 95%, 90% and 85%; the effective rate is 100%, 100% and 100%. From the data, the treatment effect on arthritis is very ideal.
And (2) clinical trial II:
the patients with moderate arthritis are averagely divided into 5 groups, each group comprises 20 patients, the medicine coating amount of each patient is the same, and the medicine amount influence factors are eliminated.
The ointment provided in example 1 was used by the first group of patients for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The second group of patients used the ointment provided in example 2 for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The third group of patients used the ointment for treating arthritis provided in example 3, using the method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The ointment for treating arthritis provided in example 4 was applied to a fourth group of patients by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The fifth group of patients served as a control group and used commercially available ibuprofen gel ointment for treating arthritis by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
After two courses of treatment, the treatment effect of each group of patients is counted, and the treatment effect is divided into clinical recovery, significant effect, effective and ineffective; the classification criteria are as follows:
the test results are shown in table 2:
TABLE 2 results of clinical trial 2
Figure BDA0002368059490000121
As seen from table 2, the clinical cure rates of the four groups of ointments for treating arthritis provided by the application to moderate arthritis patients are 75%, 70%, 65% and 65% respectively; the significant efficiency is respectively 90%, 85%, 80% and 85%; the effective rate is 100%, 100% and 100%. From the data, the treatment effect on patients with moderate arthritis is also ideal.
And (3) clinical trial three:
the patients with severe arthritis are averagely divided into 5 groups, each group comprises 20 patients, the medicine coating amount of each patient is the same, and the medicine amount influence factors are eliminated.
The ointment provided in example 1 was used by the first group of patients for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The second group of patients used the ointment provided in example 2 for the treatment of arthritis by the method of:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The third group of patients used the ointment for treating arthritis provided in example 3, using the method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The ointment for treating arthritis provided in example 4 was applied to a fourth group of patients by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
The fifth group of patients served as a control group and used commercially available ibuprofen gel ointment for treating arthritis by the following method:
applying the ointment on the affected part, massaging and kneading for ten minutes to accelerate blood circulation and promote penetration and absorption; changing the dressing once every 12 hours; a treatment course is 3 months.
After three courses of treatment, the treatment effect of each group of patients is counted, and the treatment effect is divided into clinical recovery, significant effect, effective and ineffective; the classification criteria are as follows:
the test results are shown in table 3:
TABLE 3 results of clinical trial 3
Figure BDA0002368059490000131
As shown in table 3, the clinical cure rates of the four groups of ointments for treating arthritis provided by the application are 75%, 70%, 65% and 65% for patients with severe arthritis; the significant efficiency is 85%, 80%, 75% and 85% respectively; the effective rates are 100%, 95% and 95%. From the data, the treatment effect on patients with severe arthritis is also ideal.
The experiments prove that the ointment for treating arthritis provided by the application has good curative effect on patients with mild arthritis, moderate arthritis and severe arthritis.
The medicinal components for treating arthritis provided by the application can be prepared into cream or ointment besides the ointment.
The application provides a plaster for treating arthritis, including the sheet substrate, be equipped with on the sheet substrate and paste portion and put medicine portion, it is equipped with foretell pharmaceutical composition for treating arthritis on the medicine portion to put.
However, the above description is only exemplary of the present invention, and the scope of the present invention should not be limited thereby, and the replacement of the equivalent components or the equivalent changes and modifications made according to the protection scope of the present invention should be covered by the claims of the present invention.

Claims (7)

1. The pharmaceutical composition for treating arthritis is characterized by comprising the following components in parts by weight: 5-8 parts of liquid paraffin; 5-7 parts of isopropyl palmitate; 4-7 parts of cetearyl alcohol; 4-7 parts of glycerol; 4-7 parts of menthol; 4-7 parts of chitosamine HCL; 4-6 parts of dimethyl sulfone; 3.5-5 parts of emu oil; 3.5-5 parts of squalane; 3-5 parts of polysorbate-60; 2.5-4 parts of beeswax; 2.5-4 parts of camphor; 2.5-4 parts of chondroitin sodium sulfate; 1.5-3 parts of eucalyptol; 1.5-3 parts of mussel extract; 1.5-3 parts of borneol; 1.5-3 parts of tocopherol acetate; 1-2.5 parts of an extract of the amur cork tree bark; 1-2.5 parts of polydimethylsiloxane; 0.5-2 parts of sorbitan stearate; 0.5-2 parts of glycerol stearate; 0.5-2 parts of PEG-100 stearate; 0.5-2 parts of stearic acid; ginger root oil 0.5-2 parts; 0.15-0.3 part of xanthan gum; 0.1-0.25 parts of methyl hydroxybenzoate; 0.08-0.2 part of hydroxy phenylpropyl ester; 0.1-0.2 parts of imidazolidinyl urea; 0.05-0.15 part of EDTA disodium; and a proper amount of water.
2. The pharmaceutical composition for treating arthritis according to claim 1, comprising by weight: 5-7 parts of liquid paraffin; 5-6 parts of isopropyl palmitate; 4-6 parts of cetearyl alcohol; 4-6 parts of glycerol; 4-6 parts of menthol; 4-6 parts of chitosamine HCL; 4-5 parts of dimethyl sulfone; 3.5-4.5 parts of emu oil; 3.5-4.5 parts of squalane; 3-4 parts of polysorbate-60; 2.5-3.5 parts of beeswax; 2.5-3.5 parts of camphor; 2.5-3.5 parts of chondroitin sodium sulfate; 1.5-2.5 parts of eucalyptol; 1.5-2.5 parts of mussel extract; 1.5-2.5 parts of borneol; 1.5-2.5 parts of tocopherol acetate; 1-2 parts of an extract of the amur cork tree bark; 1-2 parts of polydimethylsiloxane; 0.5-1.5 parts of sorbitan stearate; 0.5-1.5 parts of glycerol stearate; 0.5-1.5 parts of PEG-100 stearate; 0.5-1.5 parts of stearic acid; ginger root oil 0.5-1.5 weight portions; 0.15-0.25 parts of xanthan gum; 0.1-0.2 parts of methyl hydroxybenzoate; 0.08-0.15 part of hydroxy phenylpropyl ester; 0.1-0.15 parts of imidazolidinyl urea; 0.05-0.1 part of EDTA disodium; and a proper amount of water.
3. The pharmaceutical composition for treating arthritis according to claim 2, comprising by weight: 26.87 parts of water; 6 parts of liquid paraffin; 5.5 parts of isopropyl palmitate; 5 parts of cetearyl alcohol; 5 parts of glycerol; 5 parts of menthol; 5 parts of chitosamine HCL; 4.5 parts of dimethyl sulfone; 4 portions of emu oil; 4 parts of squalane; 3.5 parts of polysorbate-60; 3 parts of beeswax; 3 parts of camphor; 3 parts of chondroitin sodium sulfate; 2 parts of eucalyptol; mussel extract 2 parts; 2 parts of borneol; 2 parts of tocopherol acetate; 1.5 parts of an extract of the amur cork tree bark; 1.5 parts of polydimethylsiloxane; 1 part of sorbitan stearate; 1 part of glycerol stearate; 1 part of PEG-100 stearate; 1 part of stearic acid; 1 part of ginger root oil; 0.2 part of xanthan gum; 0.15 part of methylparaben; 0.1 part of hydroxy phenylpropyl ester; 0.13 part of imidazolidinyl urea; 0.05 part of disodium EDTA.
4. An ointment for treating arthritis is characterized by comprising the following components in parts by weight: 5-8 parts of liquid paraffin; 5-7 parts of isopropyl palmitate; 4-7 parts of cetearyl alcohol; 4-7 parts of glycerol; 4-7 parts of menthol; 4-7 parts of chitosamine HCL; 4-6 parts of dimethyl sulfone; 3.5-5 parts of emu oil; 3.5-5 parts of squalane; 3-5 parts of polysorbate-60; 2.5-4 parts of beeswax; 2.5-4 parts of camphor; 2.5-4 parts of chondroitin sodium sulfate; 1.5-3 parts of eucalyptol; 1.5-3 parts of mussel extract; 1.5-3 parts of borneol; 1.5-3 parts of tocopherol acetate; 1-2.5 parts of an extract of the amur cork tree bark; 1-2.5 parts of polydimethylsiloxane; 0.5-2 parts of sorbitan stearate; 0.5-2 parts of glycerol stearate; 0.5-2 parts of PEG-100 stearate; 0.5-2 parts of stearic acid; ginger root oil 0.5-2 parts; 0.15-0.3 part of xanthan gum; 0.1-0.25 parts of methyl hydroxybenzoate; 0.08-0.2 part of hydroxy phenylpropyl ester; 0.1-0.2 parts of imidazolidinyl urea; 0.05-0.15 part of EDTA disodium; and a proper amount of water.
5. An ointment for treating arthritis according to claim 4, comprising, by weight: 5-7 parts of liquid paraffin; 5-6 parts of isopropyl palmitate; 4-6 parts of cetearyl alcohol; 4-6 parts of glycerol; 4-6 parts of menthol; 4-6 parts of chitosamine HCL; 4-5 parts of dimethyl sulfone; 3.5-4.5 parts of emu oil; 3.5-4.5 parts of squalane; 3-4 parts of polysorbate-60; 2.5-3.5 parts of beeswax; 2.5-3.5 parts of camphor; 2.5-3.5 parts of chondroitin sodium sulfate; 1.5-2.5 parts of eucalyptol; 1.5-2.5 parts of mussel extract; 1.5-2.5 parts of borneol; 1.5-2.5 parts of tocopherol acetate; 1-2 parts of an extract of the amur cork tree bark; 1-2 parts of polydimethylsiloxane; 0.5-1.5 parts of sorbitan stearate; 0.5-1.5 parts of glycerol stearate; 0.5-1.5 parts of PEG-100 stearate; 0.5-1.5 parts of stearic acid; ginger root oil 0.5-1.5 weight portions; 0.15-0.25 parts of xanthan gum; 0.1-0.2 parts of methyl hydroxybenzoate; 0.08-0.15 part of hydroxy phenylpropyl ester; 0.1-0.15 parts of imidazolidinyl urea; 0.05-0.1 part of EDTA disodium; and a proper amount of water.
6. An ointment for treating arthritis according to claim 5, comprising, in parts by weight: 26.87 parts of water; 6 parts of liquid paraffin; 5.5 parts of isopropyl palmitate; 5 parts of cetearyl alcohol; 5 parts of glycerol; 5 parts of menthol; 5 parts of chitosamine HCL; 4.5 parts of dimethyl sulfone; 4 portions of emu oil; 4 parts of squalane; 3.5 parts of polysorbate-60; 3 parts of beeswax; 3 parts of camphor; 3 parts of chondroitin sodium sulfate; 2 parts of eucalyptol; mussel extract 2 parts; 2 parts of borneol; 2 parts of tocopherol acetate; 1.5 parts of an extract of the amur cork tree bark; 1.5 parts of polydimethylsiloxane; 1 part of sorbitan stearate; 1 part of glycerol stearate; 1 part of PEG-100 stearate; 1 part of stearic acid; 1 part of ginger root oil; 0.2 part of xanthan gum; 0.15 part of methylparaben; 0.1 part of hydroxy phenylpropyl ester; 0.13 part of imidazolidinyl urea; 0.05 part of disodium EDTA.
7. A plaster for treating arthritis, comprising a sheet-like base material provided with an adhering portion and a drug-placing portion, the drug-placing portion being provided with a pharmaceutical composition for treating arthritis according to any one of claims 1 to 3.
CN202010041930.7A 2020-01-15 2020-01-15 A pharmaceutical composition, ointment and plaster for treating arthritis Pending CN111135280A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010041930.7A CN111135280A (en) 2020-01-15 2020-01-15 A pharmaceutical composition, ointment and plaster for treating arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010041930.7A CN111135280A (en) 2020-01-15 2020-01-15 A pharmaceutical composition, ointment and plaster for treating arthritis

Publications (1)

Publication Number Publication Date
CN111135280A true CN111135280A (en) 2020-05-12

Family

ID=70525057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010041930.7A Pending CN111135280A (en) 2020-01-15 2020-01-15 A pharmaceutical composition, ointment and plaster for treating arthritis

Country Status (1)

Country Link
CN (1) CN111135280A (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873574A (en) * 2015-06-05 2015-09-02 王丽坤 Ointment for relieving pain
CN105012520A (en) * 2015-07-03 2015-11-04 北京昶沣科技有限公司 Traditional Chinese medicine ointment used for treating neck, waist, leg and joint pain and preparation method thereof
CN105012479A (en) * 2015-07-22 2015-11-04 广州科玛生物科技有限公司 Acne treatment composition and application thereof and acne treatment cream containing acne treatment composition
CN105030900A (en) * 2015-07-08 2015-11-11 吴秉民 Externally used paste for treating rheumatic and rheumatoid arthritis and its preparation method and use
CN107362177A (en) * 2017-09-07 2017-11-21 威海盛朗生物科技有限公司 Drug component, ointment and plaster for treatment of arthritis
CN108273002A (en) * 2018-03-01 2018-07-13 区门秀 A kind of transdermal ointment for treating osteoarthritis
CN108926525A (en) * 2018-09-14 2018-12-04 南方医科大学 A kind of arthritis externally applied transdermal absorption preparation
CN109010408A (en) * 2018-05-22 2018-12-18 广州市好孝心医疗器械有限公司 One kind is removed obstruction in channels to relieve pain medicinal external emulsifiable paste and preparation method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873574A (en) * 2015-06-05 2015-09-02 王丽坤 Ointment for relieving pain
CN105012520A (en) * 2015-07-03 2015-11-04 北京昶沣科技有限公司 Traditional Chinese medicine ointment used for treating neck, waist, leg and joint pain and preparation method thereof
CN105030900A (en) * 2015-07-08 2015-11-11 吴秉民 Externally used paste for treating rheumatic and rheumatoid arthritis and its preparation method and use
CN105012479A (en) * 2015-07-22 2015-11-04 广州科玛生物科技有限公司 Acne treatment composition and application thereof and acne treatment cream containing acne treatment composition
CN107362177A (en) * 2017-09-07 2017-11-21 威海盛朗生物科技有限公司 Drug component, ointment and plaster for treatment of arthritis
CN108273002A (en) * 2018-03-01 2018-07-13 区门秀 A kind of transdermal ointment for treating osteoarthritis
CN109010408A (en) * 2018-05-22 2018-12-18 广州市好孝心医疗器械有限公司 One kind is removed obstruction in channels to relieve pain medicinal external emulsifiable paste and preparation method thereof
CN108926525A (en) * 2018-09-14 2018-12-04 南方医科大学 A kind of arthritis externally applied transdermal absorption preparation

Similar Documents

Publication Publication Date Title
AU748516B2 (en) Topical drug preparations
US9220290B2 (en) Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
BG64522B1 (en) Device for the treatment of viral infectiuous diseases
EA032439B1 (en) Compositions and methods for treating surface wounds
CN106822988A (en) Alginate fibre functional dressing and its application, alginate fibre functional dressing patch
US20120034320A1 (en) Skin Penetration Composition
US6387407B1 (en) Topical drug preparations
CN111557877B (en) Toothpaste containing centella extract and preparation method thereof
CN107670027B (en) Compositions and methods for treating skin conditions
WO2004100923A1 (en) The composition for external use by percutaneous administration
CN111135280A (en) A pharmaceutical composition, ointment and plaster for treating arthritis
US20020037319A1 (en) Drug preparations
CN107596355A (en) A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof
JP2005330199A (en) Joint cream
US8900601B2 (en) Permeable mixtures, methods and compositions for the skin
CN108653431A (en) Prevent pharmaceutical composition, preparation method and applications and the preparation of rhinitis
KR100759961B1 (en) Hydrogel composition containing ketorolac tromethamine and hydrolyzed product of scutellaria radix extract
KR20120102214A (en) A medicine for external application of natural and oriental herb complex
CN1079237C (en) Dog bone scald medicine
HU207446B (en) Method for producing medicinal preparation of local use
CN115227807A (en) Gynecological gel containing recombinant human collagen and preparation method thereof
CN112121062A (en) External-use medicine composition for treating bromhidrosis
CA2390841A1 (en) Drug preparations
CN114788838A (en) Pain-relieving gel and preparation method thereof
CN117797086A (en) Anti-inflammatory acne-removing medicinal gel and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200512

RJ01 Rejection of invention patent application after publication